Publication | Closed Access

Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

UrologyGenitourinary CancerTivozanib Versus SorafenibMedicineImmune Checkpoint InhibitorCancer TreatmentOpen-label StudyOncologyRadiation OncologyMolecular OncologyPhase 3